Tactile Systems initiated with a Buy at Lake Street

Lake Street analyst Ben Haynor initiated coverage of Tactile Systems (TCMD) with a Buy rating and $23.50 price target The firm, which believes 15M-25M patients are collectively afflicted with lymphedema or bronchiectasis in the U.S., thinks only 10%-20% have been diagnosed and notes that Tactile is “the market leader” in pneumatic compression devices for LE and that the company’s AffloVest holds a number two share position in high-frequency chest wall oscillation devices for BE. Coverage headwinds have abated for Tactile and recent strategic optimizations set it up for a growth reacceleration in 2026, the analyst tells investors.